OraSure Technologies Inc
Change company Symbol lookup
Select an option...
OSUR OraSure Technologies Inc
QUOT Quotient Technology Inc
DUK Duke Energy Corp
WAFD Washington Federal Inc
REML Credit Suisse X-Links Monthly Pay 2xLeveraged Mortgage REIT ETN
$NQG3010LMT Nasdaq Global Banks Large Mid Cap To
SRTS Sensus Healthcare Inc
LITB LightInTheBox Holding Co Ltd
MZA BlackRock MuniYield Arizona
TAPR Barclays Inverse US Treasury Composite ETN

Health Care : Health Care Equipment & Supplies | Small Cap Blend
Company profile

OraSure Technologies, Inc. (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. The Company operates in two segments: OSUR and DNAG. OSUR consists of the development, manufacture and sale of diagnostic products, specimen collection devices, and medical devices. DNAG or molecular collection systems business consists primarily of the development, manufacture and sale of oral fluid collection devices that are used to collect, stabilize, and store samples of genetic material for molecular testing.

Closing Price
Day's Change
0.00 (0.00%)
B/A Size
Day's High
Day's Low

10-day average volume:

Tesla gets a 33% price target boost but stock pulls back, in danger of snapping 5-day win streak

8:02 am ET September 16, 2020 (MarketWatch)

Shares of Tesla Inc. (TSLA) dropped 2.7% in premarket trading Wednesday, to put them on track to snap a 5-day win streak, even as Deutsche Bank analyst Emmanuel Rosner boosted his price target by 33%. The electric vehicle and battery maker's stock has soared 36.2% over the past five days, to retrace 71.1% of the 34% bear-market plunge (http://www.marketwatch.com/story/tesla-stock-tumbles-toward-2nd-bear-market-in-6-months-2020-09-08) from the Sept. 1 record close of $498.32 to the Sept. 8 closing low of $331.21. Rosner raised his stock price target to $400 from $300, but reiterated his hold rating, as his new target is still 11.1% below Tuesday's closing price of $449.76. Rosner said Tesla could unveil "a new insourced manufacturing system" to ramp up battery capacity, improved cell chemistry that greaty enchances performance and "fast-declining" battery costs at its much-anticipated Battery Day scheduled for Sept. 22. "While media and investors' expectations for the event are high, we believe these announcements could meet many of them, and reinforce Tesla's position as a technology leader," Rosner wrote in a note to clients. "We believe investor ongoing enthusiasm for EV plays and the expected confirmation of ongoing technology lead by Tesla, could continue to support its high valuation." Tesla's stock has rocketed 437.6% year to date through Tuesday, while the S&P 500 has gained 5.3%.

-Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

September 16, 2020 08:02 ET (12:02 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.